Description of the use of ertapenem in a high complexity public hospital in Medellin, Colombia
Descripción del uso de ertapenem en un hospital público de alta complejidad en Medellín, Colombia
How to Cite
Download Citation
Show authors biography
Most read articles by the same author(s)
- Laura Isabel Jaramillo Jaramillo, Paula Andrea Velásquez-Viveros, Andrés Eduardo Marín Castro, Melissa Ramirez-Palacio, Eliana Cañas, Characterization of a group of patients from the anticoagulation program of a health institution and evaluation of the results of the HAS - BLED and CHA2DS2 – VASc scales, Medellín (Colombia), 2011 - 2012. , Archivos de Medicina (Manizales): Vol. 17 No. 2
Objective: to describe the use of ertapenem along with the clinical and microbiological characteristics of patients during their admission to a fourth-level health care facility in Medellin, Colombia between 2009 and 2012. Materials and Methods: a descriptive retrospective study on patients that were given antibiotic therapy with ertapenem. Results: 1390 clinical charts were reviewed, selecting 835 according to selection criteria. Ertapenem was prescribed in 36,9% for urinary tract infections and 28,1% for intraabdominal infections; 60% of the patients were located on general wards at the time of treatment with ertapenem. Microbiological cultures were performed for 84% of patients and 80% of those were positive, with 42,5% E. coli, 24,3% K. pneumoniae and 5,8% P. mirabilis. Extended spectrum betalactamases were found in 39,8% of the E. coli and 57% K. pneumoniae strains. Susceptibility of E. coli strains to ertapenem was 96,6% and 94,4% for K. pneumoniae. Conclusions: Ertapenem offers favorable results when used for the treatment of urinary tract and intraabdominal infections. It is an alternative for empirical management of infections acquired outside the hospital setting, and and as directed therapy in hospital infections.
Article visits | PDF visits
Downloads
- Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3-13. DOI: 10.1086/590061.
- Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011; 55(11):4943-60. DOI: 10.1128 / AAC.00296-11
- El-Gamal MI, Brahim I, Hisham N, Aladdin R, Mohammed H, Bahaaeldin A. Recent updates of carbapenem antibiotics. Eur J Med Chem 2017; 131:185-195. DOI: 10.1016/j.ejmech.2017.03.022.
- Gobernado M, Acuña C. Ertapenem. Rev Esp Quimioter 2007; 20(3):277-99.
- Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007; 8(2):237-56. DOI:10.1517/14656566.8.2.237
- Gómez J, García-Vázquez E, Hernández-Torres A. Betalactams in clinical practice. Rev Esp Quimioter 2015; 28(1):1-9.
- Cisterna R. Desarrollo de carbapenémicos. Ponencia. Servicio de Microbiología, Hospital de Basurto, Facultad de Medicina. Bilbao, España. [Internet]. [Citado febrero 9, 2016]. Disponible en http://www.seq.es/seq/0214-3429/18/supp1/23.pdf. incompleta
- Corona A, Singer M. An epistemological dilemma: is ertapenem adequate to treat severe infections in critically ill patients? Minerva Anestesiol 2011; 77(11):1027-9
- Comisión de Farmacia y Terapéutica. informe técnico de evaluación ertapenem. Murcia: Hospital Universitario Virgen de la Arrixaca; 2008.
- Hamouda A, Findlay J, Amyes SG. Carbapenems: do they have a future? J Med Microbiol 2011; 60(Pt 9):1229-30. DOI: 10.1099/jmm.0.031013-0.
- Maldonado N, Castro B, Berrio I, Manjarrés M, Robledo C, Robledo J. Ertapenem resistance in 2 tertiary-care hospitals: Microbiology, epidemiology, and risk factors. Enferm Infecc Microbiol Clin 2017; 35(8):511-515. DOI: 0.1016/j.eimc.2015.11.009.
- Xu ZR, Ran XW, Xian Y, Yan XD, Yuan GY, Mu SM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial. J Antimicrob Chemother 2016; 71(6):1688-96. DOI: 10.1093/jac/dkw004.
- Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt). 2007; 8(1):15-28. DOI: 10.1089/sur.2006.030.
- Yakovlev SV, Stratchounski LS, Woods GL, Adeyi B, McCarroll KA, Ginanni JA, et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis. 2006; 25(10):633-41.
- Catena F, Vallicelli C, Ansaloni L, Sartelli M, Di Saverio S, Schiavina R,et a. T.E.A. Study: three-day ertapenem versus three-day Ampicillin-Sulbactam. BMC Gastroenterol 2013; 13:76. doi: 10.1186/1471-230X-13-76.
- Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK. Meta-analysis: ertapenem for complicated intra-abdominal infections. Aliment Pharmacol Ther 2008; 27(10):919-31. DOI: 10.1111/j.1365-2036.2008.03642.x.
- Park DW, Peck KR, Chung MH, Lee JS, Park YS, Kim HY, et al. Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial. J Korean Med Sci 2012; 27(5):476-83. DOI:10.3346/jkms.2012.27.5.476.
- An MM, Zou Z, Shen H, Zhang JD, Chen ML, Liu P, et al. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials. BMC Infect Dis 2009; 9:193. DOI: 10.1186/1471-2334-9-193.
- Redondo E, Nocea G. Análisis coste-efectividad de ertapenem (Invanz®) en infecciones intraabdominales frente a piperacilina/tazobactam. Rev Esp Econ Salud 2003; 2(6):306-310.
Information
